Prestige Consumer Healthcare Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2021. Although the request metadata refers to “2020 Q4,” this filing is an annual report for fiscal 2021, with fiscal 2020 as the principal comparison.
Business context
Prestige develops, markets, sells and distributes branded over-the-counter healthcare products. Its reportable segments are North American OTC Healthcare and International OTC Healthcare. North America generated 90.0% of fiscal 2021 revenue; international markets generated 10.0%. Its portfolio includes Monistat, Summer’s Eve, BC/Goody’s, Dramamine and Fleet.
Financial performance
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Total revenue | $943.4 million | $963.0 million | Down 2.0% |
| Gross profit / margin | $547.5 million / 58.0% | $552.2 million / 57.3% | Profit down 0.9%; margin up 0.7 percentage points |
| Operating income | $297.4 million | $291.2 million | Up 2.1% |
| Net income | $164.7 million | $142.3 million | Up 15.7% |
| Diluted EPS | $3.25 | $2.78 | Up 16.9% |
| Operating cash flow | $235.6 million | $217.1 million | Up $18.5 million |
| Capital expenditures | $22.2 million | $14.6 million | Up $7.7 million |
| Interest expense, net | $82.3 million | $96.2 million | Down $13.9 million |
Gross margin improvement primarily reflected completion of the warehouse transition and improved logistics costs. Lower advertising and marketing spending also supported North American segment contribution margin, while international contribution margin declined.
Liquidity, debt and capital
- Cash and cash equivalents were $32.3 million at March 31, 2021, down from $94.8 million a year earlier. Net cash decreased $62.5 million during the year.
- Outstanding debt was $1.495 billion; balance-sheet long-term debt, net of unamortized costs, was $1.480 billion. Debt comprised $600 million of 3.750% notes due 2031, $400 million of 5.125% notes due 2028 and $495 million of term loans due 2024.
- The company had no revolving-credit borrowings and reported $132.2 million of available capacity. It made $195 million of voluntary term-loan principal payments and reported compliance with debt covenants at year-end.
- In March 2021, the company issued $600 million of 3.750% notes and redeemed $600 million of 6.375% notes. The refinancing resulted in a $12.3 million extinguishment loss, including a $9.6 million redemption premium and $2.7 million of written-off debt costs.
- The company does not expect to pay common-stock cash dividends. Debt agreements restrict certain actions, including dividends, acquisitions and share repurchases.
Changes versus the prior year
- North American revenue fell 1.2% to $849.3 million; international revenue fell 9.3% to $94.0 million. North American growth in Women’s Health, Oral Care and Analgesics partly offset declines in Cough & Cold and Gastrointestinal.
- Cough & Cold revenue declined 35.9% in North America and 38.4% internationally. Management attributed category pressure largely to fewer illness incidences and reduced travel and activity during COVID-19 restrictions.
- Net income rose despite lower revenue, aided by lower interest expense and a lower effective tax rate (19.3%, versus 25.6%). Operating cash flow increased, while cash declined amid debt repayment and other financing outflows.
- Gross margin rose from 57.3% to 58.0%; advertising and marketing expense declined to $140.6 million from $147.2 million.
Outlook, commentary and risks
- The filing provides no specific numerical revenue, earnings or cash-flow guidance. Management said it expects operating cash flow and existing credit facilities to fund working capital and capital expenditures for the next 12 months, excluding acquisitions; this is not assured.
- Management described consumer consumption and customer orders as more stable after a temporary, significant decline in fiscal 2021’s first quarter. COVID-19 effects varied by category, and further effects on demand, supply, distribution and liquidity remained uncertain.
- Prestige recorded $2.4 million of noncash impairment charges related to the Painstop brand in its international segment. A regulatory change required physician prescriptions rather than direct OTC sales; the related goodwill and finite-lived tradename were impaired. No impairment was recorded for other indefinite-lived intangibles in the annual review.
- The company began terminating its frozen U.S. qualified defined-benefit pension plan, with a termination date of April 30, 2021; completion was expected in fiscal 2023. The reported benefit obligation was $52.1 million on a termination basis.
- Key risks include reliance on Walmart (21.6% of gross revenue and 23.8% of receivables), competition and private-label products, third-party manufacturers and a single primary U.S. distribution center, input-cost inflation, COVID-19 uncertainty, and substantial goodwill and intangible assets. Total goodwill and intangible assets were $3.054 billion, most of total assets.
Important facts for investors to verify
- Whether post-pandemic demand normalizes in Cough & Cold and Gastrointestinal, and whether growth in positively affected categories persists.
- Debt repayment capacity, covenant headroom, variable-rate exposure and access to the $132.2 million revolving facility.
- Walmart and top-customer sales concentration, receivable exposure, and customer inventory or shelf-space changes.
- Progress and financial effects of the pension-plan termination, including final settlement costs and funding.
- Whether brand performance assumptions support the carrying values of goodwill and intangible assets, particularly if sales, margins or discount rates worsen.
The financial statements received an unqualified audit opinion from PwC, which also concluded internal control over financial reporting was effective as of March 31, 2021.